Who are TELOTRISTAT ETIPRATE's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telotristat-etiprate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TELOTRISTAT ETIPRATE — Competitive Intelligence Brief

TELOTRISTAT ETIPRATE (TELOTRISTAT ETIPRATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin Synthesis Inhibitor. Area: Oncology.

marketed Serotonin Synthesis Inhibitor Tryptophan Hydroxylase-1 (TPH1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TELOTRISTAT ETIPRATE (TELOTRISTAT ETIPRATE). Telotristat etiprate inhibits tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis, thereby reducing serotonin levels in the body.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TELOTRISTAT ETIPRATE TARGET	TELOTRISTAT ETIPRATE		marketed	Serotonin Synthesis Inhibitor	Tryptophan Hydroxylase-1 (TPH1)	2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-11 — TELOTRISTAT ETIPRATE · 7968559 · Method of Use · US
2027-12-11 — TELOTRISTAT ETIPRATE · 7553840 · Compound · US
2028-12-19 — TELOTRISTAT ETIPRATE · 8653094 · Method of Use · US
2031-02-27 — TELOTRISTAT ETIPRATE · 8193204 · Compound · US
2031-02-28 — TELOTRISTAT ETIPRATE · 7709493 · Compound · US

Sponsor landscape (Serotonin Synthesis Inhibitor class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TELOTRISTAT ETIPRATE — Competitive Intelligence Brief. https://druglandscape.com/ci/telotristat-etiprate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab